The FDA has approved Bimzelx® (bimekizumab-bkzx) for the treatment of moderate to severe hidradenitis suppurativa in adults.

J&J is seeking approval of TREMFYA for paediatric conditions with the submission of two sBLA to the US Food and Drug Administration.

Pharmaceutical Drug Delivery MarketThe global pharmaceutical drug delivery market is set to witness substantial growth over the next decade, with market revenue projected to rise from USD 1.9 trillion ...

CAN10 is designed to inhibit the pro-inflammatory cytokines through its action on the interleukin-1 receptor accessory ...

Cantargia (Cantargia AB; Nasdaq Stockholm:CANTA) today reported initiation of an expanded part of CAN10's phase 1 clinical study to investigate higher dose levels of the antibody. The purpose of this ...

Francis S. Kim, MD, has made significant contributions to biomedical research and clinical care for adult and pediatric ...

“The approval of Bimzelx in moderate-to-severe hidradenitis suppurativa is welcome given the substantial unmet clinical needs and limited number of treatment options available today,” BE HEARD ...

The drug survival for adalimumab is significantly higher than that of infliximab in pediatric patients with hidradenitis suppurativa (HS), results from a small single-center study showed.

Medically reviewed by Susan Bard, MD An inner thigh rash is a skin irritation that develops on the inner portion of your ...